Time filter

Source Type

Jang Y.,Peoples Hospital of Lanshan District | Lu S.A.,Jinan Central Hospital | Chen Z.P.,Shandong Provincial Qianfoshan Hospital | Ma J.,Shandong Provincial Qianfoshan Hospital | And 3 more authors.
Genetics and Molecular Research | Year: 2013

Cyclin D1 (CCND1) plays a significant role in G1-S transition of cell cycle, and phosphatase and a tensin homologue (PTEN) negatively regulate cell cycle through phosphatidylinositol 3-kinase (PI3K)/AKT signaling. CCND1 and PTEN genetic polymorphisms might induce susceptibility to the occurrence of esophageal squamous cell carcinoma (ESCC). Three hundred and four ESCC patients and 413 healthy controls from Anyang, China, were enrolled in this study. All genotyping at CCND1 (807 G/A) and PTEN (rs701848 T/C and rs2735343 C/G) were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Unconditional logistic regression model was used to analyze the correlation between the polymorphisms and the susceptibility to develop ESCC. Statistically significant differences were observed between cases and controls in distribution of genotypes or alleles at PTEN rs701848 T/C and rs2735343 C/G, with either haplotype TG or CG possessing notably higher proportion in cases than in the controls. However, such difference could not be found in the distribution of the polymorphisms at CCND1 807 G/A. In summary, the polymorphisms of PTEN rs701848 T/C and rs2735343 C/G might represent crucial modifying factors for development of ESCC. © FUNPEC-RP. Source

Li X.-L.,Peoples Hospital of Rizhao | Ding M.-Y.,Peoples Hospital of Lanshan District | Sun R.-Z.,Hubei University | Wang Q.,Hubei University | And 5 more authors.
Tumor | Year: 2014

Objective: To investigate the expression status of chromatin assembly factor 1, subunit A (CHAF1A) in human multiple tumors, clarify the relationship between CHAF1A expression and clinicopathological features of patients with hepatocellular carcinoma, breast cancer and lung cancer, and evaluate the function of CHAF1A as a prognostic marker in these cancers. Methods: GEO (Gene Expression Omnibus) datasets were collected from National Center for Biotechnology Information (NCBI) website. The tumor sample expression profile including CHAF1A expression data and its clinical information were downloaded. The correlation between CHAF1A gene expression and the clinicopathologic features was analyzed by Chi-square test. Overall survival and recurrence-free survival were analyzed by Kaplan-Meier method. GSEA (gene set enrichment analysis) was used to predict the gene sets modulated by CHAF1A. Results: The expressions of CHAF1A were up-regulated in hepatocellular carcinoma, colorectal cancer, esophageal carcinoma, lung cancer, ovarian cancer, melanoma, nasopharyngeal carcinoma and gastric cancer (all P 〈 0.05). CHAF1A expression was associated with p53 deficiency, p53 mutation, estrogen receptor (ER) expression, progesterone receptor (PR) expression and Elston histologic grade in patients with breast cancer (all P 〈 0.05), and it was also associated with the age, gender, T stage, lymph node metastasis and distant metastasis in patients with lung cancer (all P 〈 0.05). High level of CHAF1A expression indicated poor prognosis of patients with hepatocellular carcinoma, breast cancer and lung cancer (all P 〈 0.05). CHAF1A could regulate gene sets involving cell cycle regulation, DNA replication and cytoskeleton regulation. Conclusion: CHAF1A is highly expressed in multiple tumors, and it maybe used as a potential prognostic marker and a therapeutic target. Copyright© 2014 by TUMOR. Source

Liu M.,Shandong University | Hu Y.,Shandong University | Li G.,Shandong University | Hu W.,Peoples Hospital of Lanshan District
International Journal of Endocrinology | Year: 2015

Objective. The follow-up of GH levels in short-stature children with pituitary hyperplasia secondary to primary hypothyroidism (PPH) is reported in a few cases. We aimed to observe changes in GH secretion in short-stature children with PPH. Methods. A total of 11 short-stature children with PPH accompanied by low GH levels were included. They received levothyroxine therapy after diagnosis. Their thyroid hormones, IGF-1, PRL, and pituitary height were measured at baseline and 3 months after therapy. GH stimulation tests were performed at baseline and after regression of thyroid hormones and pituitary. Results. At baseline, they had decreased GH peak and FTand FTlevels and elevated TSH levels. Decreased IGF-1 levels were found in seven children. Elevated PRL levels and positive thyroid antibodies were found in 10 children. The mean pituitary height was 14.3 ± 3.8 mm. After 3 months, FT FT and IGF-1 levels were significantly increased (all p < 0.01), and values of TSH, PRL, and pituitary height were significantly decreased (all p < 0.001). After 6 months, pituitary hyperplasia completely regressed. GH levels returned to normal in nine children and were still low in two children. Conclusion. GH secretion can be resolved in most short-stature children with PPH. © 2015 Minghua Liu et al. Source

Li D.,University of Sichuan | Ye Y.,University of Sichuan | Li D.,Peoples Hospital of Lanshan District | Li X.,Southwest University for Nationalities | Mu C.,University of Sichuan
Carbohydrate Polymers | Year: 2016

Gelatin-based composite hydrogel fibers were prepared by gel-spinning with PEG6000 as the modifier. Dialdehyde carboxymethyl cellulose (DCMC), as an ideal crosslinking reagent for protein, was used to fix the composite hydrogel fibers. Then the biological properties of the hydrogel fibers for wound dressings were evaluated. The results indicate that the hydrogen bond interactions and C=N linkages between gelatin and DCMC can be formed. The addition of DCMC can efficiently improve the mechanical properties, enzymatic stability and blood compatibility of the hydrogel fibers. Crosslinking with DCMC can reduce the degree of swelling of the hydrogel fibers, which is beneficial for hydrogel fibers to avoid undesired reduction in mechanical properties. Moreover, the composite hydrogel fibers present three-dimensional structure, porous networks and low cytotoxicity. The study suggests that DCMC is an effective crosslinking reagent for biomaterials fixation. The developed composite hydrogel fibers can be well-suited for biomedical applications such as wound dressings. © 2015 Elsevier Ltd. All rights reserved. Source

Hu Y.-Y.,Shandong University | Li G.-M.,Shandong University | Hu W.-W.,Peoples Hospital of Lanshan District | Wang Y.,Shandong University
Acta Paediatrica, International Journal of Paediatrics | Year: 2014

Aim To investigate the different characteristics of girls with pituitary hyperplasia secondary to primary hypothyroidism (PPH), with and without sexual precocity. Methods Pituitary hyperplasia secondary to primary hypothyroidism girls were divided into two groups: group A, with sexual precocity (n = 8), and group B, without sexual precocity (n = 14). The following values were measured before and after 3 months levothyroxine therapy: free triiodothyronine (FT 3), free thyroxine (FT4), thyrotropin (TSH), follicle-stimulating hormone (FSH), luteinising hormone (LH), prolactin (PRL), estradiol (E2), testosterone (T), pituitary height, uterine volume (UV), ovarian volume (OV) and follicular diameter (FD). Results Thyrotropin, FSH, PRL, E2, T, pituitary height, UV, OV and FD were higher in group A than group B (all p < 0.05); FT3, FT4 and LH levels were not different (all p > 0.05). In all of the PPH girls, pituitary height was correlated with FT3, FT4 and PRL (r = -0.545, p = 0.009, r = -0.567, p = 0.006 and r = 0.666, p = 0.001, respectively). PRL was positively correlated with UV, FD and FSH (r = 0.581, p = 0.005, r = 0.482, p = 0.031 and r = 0.667, p = 0.001, respectively), and FSH was positively correlated with OV (r = 0.522, p = 0.013). These abnormalities regressed after therapy. Conclusion Pituitary hyperplasia secondary to primary hypothyroidism girls with sexual precocity have increased plasma TSH, FSH, PRL, E2 and T levels, pituitary height and uterine, ovarian and follicular size. © 2013 Foundation Acta Pædiatrica. Published by John Wiley & Sons Ltd. Source

Discover hidden collaborations